Tenet Healthcare Corporation $THC Holdings Raised by Dorsey Wright & Associates

Dorsey Wright & Associates increased its position in shares of Tenet Healthcare Corporation (NYSE:THC) by 29.4% during the 1st quarter, HoldingsChannel.com reports. The firm owned 69,990 shares of the company’s stock after purchasing an additional 15,895 shares during the period. Tenet Healthcare accounts for 1.6% of Dorsey Wright & Associates’ investment portfolio, making the stock its 19th biggest position. Dorsey Wright & Associates’ holdings in Tenet Healthcare were worth $13,208,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Swedbank AB raised its stake in Tenet Healthcare by 14.7% during the fourth quarter. Swedbank AB now owns 146,133 shares of the company’s stock worth $29,040,000 after acquiring an additional 18,750 shares during the period. Brandywine Global Investment Management LLC boosted its stake in Tenet Healthcare by 20.5% in the fourth quarter. Brandywine Global Investment Management LLC now owns 126,248 shares of the company’s stock valued at $25,088,000 after acquiring an additional 21,435 shares during the period. M&T Bank Corp grew its holdings in shares of Tenet Healthcare by 1,944.8% during the fourth quarter. M&T Bank Corp now owns 104,304 shares of the company’s stock valued at $20,727,000 after purchasing an additional 99,203 shares during the last quarter. Hsbc Holdings PLC raised its position in shares of Tenet Healthcare by 3,478.7% during the 4th quarter. Hsbc Holdings PLC now owns 266,400 shares of the company’s stock worth $53,269,000 after purchasing an additional 258,956 shares during the period. Finally, Sivia Capital Partners LLC acquired a new position in Tenet Healthcare during the 2nd quarter valued at approximately $290,000. Institutional investors own 95.44% of the company’s stock.

Insider Buying and Selling at Tenet Healthcare

In other Tenet Healthcare news, Director J Robert Kerrey sold 5,638 shares of Tenet Healthcare stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $174.52, for a total transaction of $983,943.76. Following the transaction, the director owned 16,804 shares of the company’s stock, valued at $2,932,634.08. The trade was a 25.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Nadja West sold 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $177.35, for a total transaction of $532,050.00. Following the completion of the transaction, the director owned 24,805 shares in the company, valued at approximately $4,399,166.75. This represents a 10.79% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.97% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

THC has been the topic of several analyst reports. Wells Fargo & Company increased their target price on Tenet Healthcare from $213.00 to $231.00 and gave the stock an “overweight” rating in a research report on Monday. KeyCorp lowered their price target on shares of Tenet Healthcare from $250.00 to $225.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Morgan Stanley set a $254.00 price objective on shares of Tenet Healthcare in a research report on Friday, May 1st. Stephens reduced their target price on shares of Tenet Healthcare from $275.00 to $260.00 and set an “overweight” rating for the company in a research note on Monday, May 4th. Finally, Robert W. Baird cut their price target on Tenet Healthcare from $245.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, May 5th. Eighteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, Tenet Healthcare presently has a consensus rating of “Moderate Buy” and a consensus price target of $245.37.

Tenet Healthcare Stock Performance

NYSE:THC opened at $194.89 on Friday. The company has a 50-day moving average of $184.35 and a 200-day moving average of $197.48. The firm has a market cap of $16.79 billion, a price-to-earnings ratio of 10.13, a price-to-earnings-growth ratio of 1.65 and a beta of 1.27. The company has a current ratio of 1.36, a quick ratio of 1.30 and a debt-to-equity ratio of 1.96. Tenet Healthcare Corporation has a twelve month low of $146.60 and a twelve month high of $247.21.

Tenet Healthcare (NYSE:THC) last released its quarterly earnings data on Thursday, April 30th. The company reported $4.82 earnings per share for the quarter, topping the consensus estimate of $4.21 by $0.61. The business had revenue of $5.37 billion during the quarter, compared to analyst estimates of $5.39 billion. Tenet Healthcare had a return on equity of 25.55% and a net margin of 7.94%.The company’s revenue was up 2.6% compared to the same quarter last year. During the same period last year, the company posted $4.36 EPS. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. Analysts forecast that Tenet Healthcare Corporation will post 17.5 earnings per share for the current fiscal year.

Tenet Healthcare Company Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.